GlassScriptPhysician profile
Jonathan Parker Wilmot
NPI 1750606141
$5,895.47
in general payments reported to CMS, 2019-2025
39 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $332 · 2021: $784 · 2022: $728 · 2023: $596 · 2024: $1,248 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.79 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $1,274.05 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.37 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $428.19 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ferring Pharmaceuticals INC. | $267.86 | 2019-2025 | Rebyota |
| Ardelyx, INC. | $258.83 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $211.77 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $139.65 | 2021-2025 | Suflave, Sutab |
| Ucb, INC. | $124.21 | 2019-2020 | |
| Gilead Sciences, INC. | $104.34 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $100.42 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $97.54 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $92.84 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $92.60 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $91.28 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $89.64 | 2022-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $79.96 | 2025 | Iqirvo |
| Olympus America INC. | $76.72 | 2024 | |
| Nestle Healthcare Nutrition INC. | $75.60 | 2021-2023 | |
| Pfizer INC. | $74.41 | 2020-2025 | |
| Exact Sciences Corporation | $52.59 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $46.71 | 2020-2024 | Dificid |
| Organon LLC | $44.43 | 2024-2025 | Hadlima |
| Madrigal Pharmaceuticals | $40.61 | 2025 | Rezdiffra |
| Qol Medical, LLC | $30.26 | 2019-2020 | |
| Cook Medical LLC | $28.67 | 2021-2023 | Caesar |
| Amgen INC. | $27.18 | 2023 | Avsola, Amjevita |
| Novo Nordisk INC | $26.26 | 2025 | Wegovy |
| Redhill Biopharma INC. | $20.71 | 2021 | |
| Daiichi Sankyo INC. | $19.19 | 2021 | |
| Genzyme Corporation | $18.25 | 2024 | |
| Aries Pharmaceuticals, INC. | $15.09 | 2019 | |
| Sandoz INC. | $14.55 | 2024 | Hyrimoz |
| Endo Pharmaceuticals INC. | $13.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2024 | Simlandi |
| Astrazeneca Pharmaceuticals LP | $12.58 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wilmot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.